Purpose:To assess the reproducibility of intrinsic relaxivity and both relaxivity-and susceptibility-based dynamic contrast enhanced (DCE) MRI in pelvic tumors; to correlate kinetic parameters obtained and to assess whether acute antivascular effects are seen in response to cisplatin-or taxane-based chemotherapy. Materials and Methods:T 1 -weighted and T 2 *-weighted DCE-MRI and basal R 2 * measurements were performed on three consecutive days in women with gynecological tumors. The third scan was 21.0 (range 17.3-23.5) hours after the first cycle of chemotherapy. Kinetic parameter estimates were obtained and correlated between techniques. Test-retest reproducibility and response to treatment were assessed. Results:Relative blood volume (rBV) and relative blood flow (rBF) correlated strongly with transfer constant (K trans ), k ep , and the initial area under the gadopentetate dimeglumine (Gd-DTPA) concentration-time curve (IAUGC) (all P Ͻ 0.01). The group 95% confidence interval (CI) for change was -10.8 to ϩ12.1%; Ϯ5.1%; -9.5 to ϩ10.5%; Ϯ7.5%; for K trans , v e , k ep , and IAUGC, respectively, and Ϯ13.6%, Ϯ2.4%, Ϯ11.6%, and Ϯ11.0%, for rBV, mean transit time (MTT), rBF, and R 2 *, respectively. There were no significant acute changes in kinetic parameter estimates in response to treatment on group analysis, apart from a small decrease in v e . Conclusion:The results confirm the dominant influence of flow on K trans in untreated gynecological tumors. There is no evidence of an acute, large magnitude antivascular effect caused by cisplatin-or taxane-based chemotherapy.

Hepatic metastases are arterially supplied, resulting in an elevated hepatic perfusion index (HPI). The purpose of this study was to use dynamic contrast-enhanced (DCE) MR imaging to quantify the HPI of metastases and the liver before and after treatment with a novel antiangiogenic drug. Ten patients with known metastatic liver disease underwent DCE-MR studies. HPIs of metastases and whole liver were derived using regions of interest (ROIs) and calculated on a pixel-by-pixel basis from quantified changes in gadopentetate dimeglumine (Gd-DTPA) concentration. The HPI measurement error prior to treatment was derived by the Bland-Altman analysis. The median HPI before and after treatment with antiangiogenic drug BIBF 1120 were compared using the Wilcoxon signed rank test. Prior to treatment, the median HPI of metastases, 0.75 +/- 0.14, was significantly higher than that of the whole liver, 0.66 +/- 0.16 (p < 0.01). Bland-Altman reproducibility coefficients of the median HPI from metastases and whole liver were 13.0 and 5.1% respectively. The median HPI of metastases decreased significantly at 28 days after treatment with BIBF 1120 (p < 0.05). This pilot study demonstrates that HPI determined using quantified Gd-DTPA concentration is reproducible and may be useful for monitoring antiangiogenic treatment response of hepatic metastases.